(NYSE: ADCT) Adc Therapeutics Sa's forecast annual revenue growth rate of 21.13% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Adc Therapeutics Sa's revenue in 2025 is $75,817,000.On average, 2 Wall Street analysts forecast ADCT's revenue for 2025 to be $7,728,963,828, with the lowest ADCT revenue forecast at $7,543,500,433, and the highest ADCT revenue forecast at $7,914,427,223. On average, 1 Wall Street analysts forecast ADCT's revenue for 2026 to be $11,564,188,148, with the lowest ADCT revenue forecast at $11,564,188,148, and the highest ADCT revenue forecast at $11,564,188,148.
In 2027, ADCT is forecast to generate $12,913,012,837 in revenue, with the lowest revenue forecast at $12,913,012,837 and the highest revenue forecast at $12,913,012,837.